Learning from other diseases: protection and pathology in chronic fungal infections

被引:0
作者
Teresa Zelante
Giuseppe Pieraccini
Lucia Scaringi
Franco Aversa
Luigina Romani
机构
[1] University of Perugia,Pathology, Department of Experimental Medicine
[2] Mass Spectrometry Centre (CISM) of the University of Florence,Department of Hematology
[3] University of Parma,undefined
来源
Seminars in Immunopathology | 2016年 / 38卷
关键词
Mycobiome; Fungal infection; Kynurenine; IDO; AhR;
D O I
暂无
中图分类号
学科分类号
摘要
Fungal commensals coexist in a complex milieu of bacteria within the human body. An increased understanding of the importance of microbiota in shaping the host’s immune and metabolic activities has rendered fungal interactions with their hosts more complex than previously appreciated. Metagenomics has revealed the complex interactions between fungal and bacterial commensals that, either directly or through the participation of the host immune system, impact on immune homeostasis at mucosal surfaces that, in turn, lead to secondary fungal infections. Metabolomics has captured the dialogue between the mammalian host and its microbiota. It appears that the host tryptophan catabolic enzyme, indoleamine 2,3-dioxygenase 1 (IDO1) plays a dominant role in the interplay between tryptophan catabolism by microbial communities, the host’s own pathway of metabolite production, and the activation of the aryl hydrocarbon receptor (AhR)/IL-22 axis, eventually impacting on mucosal immune homeostasis and host/fungal symbiosis. Thus, the regulatory loop involving AhR and IDO1 may be exploited for the development of multi-pronged host- and microbiota-directed therapeutic approaches for mucosal and systemic fungal diseases.
引用
收藏
页码:239 / 248
页数:9
相关论文
共 953 条
  • [1] Romani L(2011)Immunity to fungal infections Nat Rev Immunol 11 275-288
  • [2] Segal BH(2008)Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria Clin Infect Dis 47 674-683
  • [3] Herbrecht R(2013)The emerging world of the fungal microbiome Trends Microbiol 21 334-341
  • [4] Stevens DA(2013)The human mycobiome in health and disease Genome Med 5 63-3200
  • [5] Ostrosky-Zeichner L(2014)Microbiota control of a tryptophan-AhR pathway in disease tolerance to fungi Eur J Immunol 44 3192-474
  • [6] Sobel J(2015)British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases Lancet Infect Dis 15 461-416
  • [7] Viscoli C(2014)The mycobiota: interactions between commensal fungi and the host immune system Nat Rev Immunol 14 405-841
  • [8] Walsh TJ(2010)Characterization of the oral fungal microbiome (mycobiome) in healthy individuals PLoS Pathog 6 831-87
  • [9] Maertens J(2008)Fungi and inflammatory bowel diseases: alterations of composition and diversity Scand J Gastroenterol 43 77-498
  • [10] Patterson TF(2013)Archaea and fungi of the human gut microbiome: correlations with diet and bacterial residents PLoS One 8 492-702